argenx SE (1AE.F)

Compare

600.20

+10.20

+(1.73%)

At close: 8:18:52 AM GMT+1

Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says

Argenx's (ARGX) Q4 sales of $737 million, up 29% quarter-on-quarter, were backed by increasing Vyvga

PREMIUM
MT Newswires 3 days ago

ARGX
Exploring 3 High Growth Tech Stocks in Europe

Amid cautious optimism in Europe, the pan-European STOXX Europe 600 Index recently edged higher by 0.26% as investors weighed developments in U.S. trade policy and efforts to resolve the Russia-Ukraine conflict, while eurozone business activity showed signs of stagnation despite remaining in expansionary territory. In such a dynamic market environment, identifying high-growth tech stocks often involves looking for companies that demonstrate strong innovation capabilities and resilience to...

Simply Wall St. 3 days ago

IZER.MC

PRS.MC

ARGNF
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET

GlobeNewswire 4 days ago

ARGNF

ARGX
argenx to Present at TD Cowen 45th Annual Healthcare Conference

February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay

GlobeNewswire 6 days ago

ARGNF

ARGX
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

A handful of biotech stocks made an elite list despite being unprofitable. But many show robust sales growth and constructive charts.

Investor's Business Daily 10 days ago

BEIGF

ONC

ARGNF
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx w

GlobeNewswire 11 days ago

ARGNF

ARGX
Here’s Why argenx SE (ARGX) Rose in Q4

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging quarter for the larger health care industry. A copy of the letter can be downloaded here. The fund declined 9.58% (Institutional Shares) in the quarter compared […]

Insider Monkey 12 days ago

ARGX
Q4 2024 Halozyme Therapeutics Inc Earnings Call

Q4 2024 Halozyme Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 12 days ago

HALO

JNJ

ARGX
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.

Zacks last month

ARGX
Exploring High Growth Tech Stocks With Promising Potential

As global markets experience a surge, with U.S. stocks reaching new heights amid optimism over trade policies and AI advancements, growth stocks have notably outperformed their value counterparts, highlighting investor enthusiasm for innovation-driven sectors. In this dynamic environment, identifying high-growth tech stocks involves evaluating companies that can leverage technological advancements and strategic partnerships to capitalize on emerging market opportunities.

Simply Wall St. last month

ARGNF

ARGX
Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other high growth international stocks to invest in now. What To Expect From The Stock Market in 2025? On January 15, Jurrien Timmer, […]

Insider Monkey last month

ARGX
Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against other high growth international stocks to invest in now. What To Expect From The Stock Market in 2025? On January 15, Jurrien […]

Insider Monkey last month

ASND

ARGX
Earnings Estimates Rising for Argenx (ARGX): Will It Gain?

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks last month

ARGX
argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm 10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of indications Empasiprubart to be evaluated in two head-to-head registrational studies against IVIg to position C2 inhibitor for broad, early-line use in MMN and

GlobeNewswire last month

ARGNF

ARGX
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl

GlobeNewswire last month

ARGNF

ARGX
Exploring High Growth Tech Stocks for January 2025

As we enter January 2025, global markets are navigating a landscape marked by fluctuating consumer confidence and mixed economic indicators, with major U.S. stock indexes experiencing moderate gains amidst a holiday-shortened trading week. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential and market adaptability, particularly as the technology-heavy Nasdaq Composite continues to show resilience despite recent...

Simply Wall St. last month

ARGNF

ARGX
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

Argenx Se ( (ARGX) ) has provided an update. Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks the first time the neonatal Fc receptor blocker has been authorized for CIDP treatment, providing patients with a convenient at-home self-injection option. The approval is based on the results of the ADHERE trial, which demonstrated significant clinical improvements i

TipRanks 2 months ago

ARGNF

ARGX
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications December 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of

GlobeNewswire 2 months ago

ARGNF

ARGX
Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and […]

Insider Monkey 2 months ago

ARGX
Here’s Why argenx SE (ARGX) Surged in Q3

PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. […]

Insider Monkey 2 months ago

ARGX

Performance Overview

Return	1AE.F	BEL 20
YTD	-0.10%	+5.77%
1-Year	+71.29%	+20.84%
3-Year	+130.14%	+12.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

argenx SE (1AE.F)

Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says

Exploring 3 High Growth Tech Stocks in Europe

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

Here’s Why argenx SE (ARGX) Rose in Q4

Q4 2024 Halozyme Therapeutics Inc Earnings Call

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Exploring High Growth Tech Stocks With Promising Potential

Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

Earnings Estimates Rising for Argenx (ARGX): Will It Gain?

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Exploring High Growth Tech Stocks for January 2025

Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?

Here’s Why argenx SE (ARGX) Surged in Q3

Performance Overview